You searched for "haemostatic"

280 results found

Immunotherapy in renal cancer

Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...

Prostate abscess

Prostate abscess (PA) is a relatively uncommon clinical condition which is often difficult to diagnose because clinical symptoms are non-specific. It may be associated with a significant fatality rate, estimated to be between 3% and 30%, which may reflect its...

Non-urologist non-physician assessment of scrotal pain using the TWIST score

Testicular torsion is a urological emergency that requires prompt diagnosis and intervention. Some providers are becoming increasingly dependent on ultrasound (US) to make the diagnosis. This NIH clinical trial evaluated the use of the TWIST (Testicular Workup for Ischaemia and...

MOWOOT II Intestinal Transit Management System

MOWOOT II is an intermittent colonic exo-peristaltic therapy system for intestinal transit disorders, such as slow transit constipation. MOWOOT II utilises advanced pneumatic technology to treat and prevent chronic constipation without laxatives, enemas...

PDE5I in LUTS – how do they work – no proof yet

Phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction (ED) have been shown to improve lower urinary tract symptoms (LUTS) as well. The mechanism is not well understood. One of the hypotheses for benign prostatic hyperplasia (BPH) – LUTS is...

Recent developments in bladder cancer

There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...

Metastatic spinal cord compression – a review

Introduction Metastatic spinal cord compression (MSCC) is an oncological emergency that, unless diagnosed early and treated appropriately, can lead to significant morbidity and mortality, including paralysis and bladder and bowel dysfunction. MSCC can be defined as spinal cord or cauda...

Impact of MetS on prostate cancer (PCa)

Metabolic syndrome is associated with an increased risk of finding prostate cancer (PCa) overall and high-grade disease on biopsy. The first objective was to determine if MetS is associated with higher final PCa stage and grade on radical prostatectomy (RP)...

Active surveillance for small renal masses in younger patients

Active surveillance (AS) is discussed as an option for renal masses <2cm in patients with significant competing risks for mortality. This multicentre data from the US seeks to fill an important gap in current guidelines for provision of this option...

RSM: Urothelial cancer: advances, innovation and improving outcomes

Why attend? Hear from leading experts including Professor Param Mariappan, Professor Tom Powles, Professor Ben Challacombe and Professor Alison Birtle Explore how quality improvement initiatives, including lessons from Scotland's bladder cancer KPI programme, are shaping care delivery. Gain updates on...

PARP inhibitors and prostate cancer

The discovery that BRCA1/2-deficient tumour cells are highly sensitive to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) established the foundation of synthetic lethality in metastatic castration-resistant prostate cancer (mCRPC). The TOPARP-A trial confirmed clinical benefit, with PARPi activity largely restricted to...

Assessment and management of percutaneous nephrostomies

Nephrostomies are a valuable uroradiological intervention which enables drainage of the obstructed kidney, amongst other indications. Complications associated with nephrostomies following placement are not uncommon, with re-presentation to the emergency department or surgical emergency unit. In this review we will...